The First 8 Weeks: The Hidden Battleground in India’s Weight-Loss Drug Market

By Satish Srivastava

📌 Executive Summary 

Early signals from weight-loss therapy launches suggest that the biggest barrier to market growth may not be pricing, but early discontinuation. Most patients stop within the first six to eight weeks - often due to a gap between expectations and early experience. 

Designing this initial period more deliberately, supported by digital patient engagement, can improve persistence, strengthen perceived value, and support sustainable category expansion. 

  

Everyone is debating pricing in the weight-loss therapy market.

• Premium vs access

• Affordability vs margins

• Volume vs value

These are important questions. But they may not be the ones that ultimately shape how this market evolves.

Because early adoption patterns are pointing to something else. The biggest challenge is not getting patients to start therapy - it’s helping them stay long enough to experience meaningful outcomes. And most of the drop-offs seem to happen in the first 6 - 8 weeks.

From Digital Touchpoints to Real Prescriptions

What a 2-Year Paediatrician Program in India Taught Us About Revenue-Grade Digital Engagement

Executive Summary This case study outlines how a two-year digital engagement program with paediatricians in India moved beyond engagement metrics to deliver measurable commercial outcomes. By onboarding over 6,600 digitally ready paediatricians and combining scientific digital outreach with targeted tele-engagement, the program successfully created more than 2,300 new prescribers and generated 55,000+ digitally attributable prescriptions. Importantly, digital was positioned not as a replacement for field teams but as a prescriber creation engine, with converted doctors systematically handed over to ground sales teams for long-term value realization. The experience demonstrates that when digital is designed around prescriber creation, disciplined attribution, and clear field integration, it can evolve from a communication channel into a scalable revenue lever.

For years, digital in pharma has been measured by opens, clicks, and likes.

Yet commercial teams continue to ask the same uncomfortable question:

“Does any of this actually move prescriptions?”

Are We Rewarding the Past or Building the Future?

 

Happy New Year from DigiRx

As the year closes, many of us pause to reflect - on what we built, what we defended, and what we might do differently going forward.
In pharma, this reflection matters more than ever.

Across conversations with leadership teams this year - including a recent discussion with a friend who heads a large mass-specialty business - one theme kept resurfacing:

Our industry is not limited by talent or intent.
It is limited by what we choose to measure.

This post is not a criticism.
It is a New Year invitation - gentle food for thought for all of us building future-ready organisations.

Beyond Digital - Part 3 : "The 3×3 Hybrid Personalization System for Modern Pharma"

The 3×3 Hybrid Personalization System for Modern Pharma

By Satish Srivastava

Missed Part 1 or 2 ? Read it here:
👉 Part 1 - (Commercial Excellence Reimagined)

👉 Part 2 - Rewiring Sales Models - A Leadership Narrative

---

Personalization is no longer an aspiration - it is a commercial necessity. What the industry needs now is a practical system that defines:

• What runs at the front-end

• What powers it at the back-end

• Who does what

• How all components interact

• How to execute personalization without complexity

This post introduces a complete, implementation-ready 3×3 Hybrid Personalization Engine designed for Indian pharma.

The Infinite vs. Finite Game: A Founder's Lens

By Satish Srivastava

As I prepare to release Part 3 of the Beyond Digital series, I felt the need to pause and reflect on a question that has come up repeatedly over the last couple of weeks:

Do businesses really need VC funding to scale in the digital era?

Rewiring Sales Models — A Leadership Narrative, (Beyond Digital — Part 2)

Rewiring Sales Models - A Leadership Narrative

(Beyond Digital - Part 2)

By Satish Srivastava

Missed Part 1? Read it here:
👉 Part 1 - (Commercial Excellence Reimagined)

---

A few months ago, I was reviewing performance data across three therapy areas.

Three different teams. Three different customer bases.
But the pattern was identical:

Strong field force → weak digital integration → inconsistent impact.

During one of those discussions, a BU Head said something that stayed with me:

“Satish, our reps are working harder than ever. But doctors are harder to reach, and marketing is adding digital without a plan. We’re playing two different games on the same field.”

That’s when it hit me.

Pharma is not struggling because of a lack of reps.
Pharma is not struggling because digital doesn’t work.
Pharma is struggling because the model itself is outdated.

Commercial Excellence Reimagined: From Calls to Customer Value (Beyond Digital- Part-1)

A few years ago, success in pharma sales was simple to define - or at least we thought it was.

Hit your call average, maintain coverage, close the month strong. That was “excellence.”

But as the world changed - as digital channels, data, and hybrid models entered our daily vocabulary

Beyond Digital: Unlocking Pharma’s Enterprise Value- “ The DigiRx series exploring what drives real impact beyond activity”

Over the last few months on DigiRx, I’ve been reflecting on how pharma’s digital transformation is reshaping the way we engage, sell, and create value — from omnichannel engagement to hybrid sales models and personalized HCP experiences.

And through all these conversations, one essential question keeps surfacing:

How do we translate digital success into true commercial excellence?

That’s where this new series begins — a journey to explore what lies beyond digital activity, and how real commercial excellence is built.

In this upcoming set of posts, I’ll unpack the evolution from Digital Sales to Commercial Excellence — not as a technology story,

Over 12 Months, 110K Doctors, 800K Interactions: How Virtual Reps Turned Digital Hesitation into HCP Adoption

When I launched DigiRx with Satish, I made a promise: this would be an evidence-led space. Not just theory or hype, but real outcomes from real-world projects.

Drawing on many years of experience in digital HCP engagement, I’m sharing insights from the latest trailing 12 months (September 2023 - August 2024) to provide an unbiased, real-world perspective. During this period, I led multiple digital adoption projects across India and Africa with both global and Indian pharma MNCs. These initiatives spanned chronic and acute therapies, involved HCPs across diverse geographies and ethnicities, and applied a repeatable V-Rep adoption model that consistently drives measurable business outcomes.

This case study summarizes the problem we addressed, the solution we built, the business impact achieved, and the broader opportunities ahead.

AI Ethics and Trust: The Missing Link in Smarter Pharma Engagement

Would you trust an algorithm to decide what medical information your doctor sees—and when?

It sounds futuristic, but in reality, we are already living in that world. From personalized emails to chatbot-driven support and predictive targeting, artificial intelligence is quietly shaping how healthcare professionals (HCPs) engage with pharma companies. The pitch is simple: faster, smarter, more relevant.

But here’s the paradox—while AI can scale engagement, it can also fracture trust if used carelessly. In an industry where credibility is everything, the wrong click, the wrong recommendation, or even the wrong timing of a message can make an HCP question not just the technology, but the company behind it.

---

Why This Matters Now

Pharma has never been more invested in AI. From optimizing rep calls to generating medical content to predicting which doctors engage digitally—pilots are everywhere. The potential is massive: saving time, reducing costs, improving relevance.

Meanwhile, HCPs are more digitally native than ever. They expect convenience, personalization, and scientific accuracy—but are also alert to bias, privacy intrusions, and manipulation.

At the same time, regulators are stepping in. The EU’s AI Act, India’s PDP Bill, GDPR in Europe, and the FDA’s evolving stance are clear signals: pharma can no longer treat AI as an experimental toy. Ethics, compliance, and transparency will define who leads—and who gets left behind.

The real risk isn’t whether the algorithm “works.” It’s whether it erodes trust.

So the question is not “How do we use AI in pharma engagement?”
It’s “What are we scaling—and can it be trusted?”

Unlocking Enterprise Value: From Digital Sales to Commercial Excellence in Pharma

 

Part 3: The Leadership Playbook - Scaling Digital as a Strategic Capability

In Part-1, we uncovered why digital sales needs to evolve from functional efficiency to enterprise value creation.
In Part-2, we explored operational levers-customer intelligence, precision launch, cross-functional alignment, and value-focused metrics-that make this transformation real.

But no transformation sticks without leadership orchestration.

In this final part, we’ll lay out a practical leadership playbook to embed digital as a strategic capability-not a side project-so it can scale across therapy areas, geographies, and commercial teams.

Unlocking Enterprise Value: From Digital Sales to Commercial Excellence in Pharma

 

Part 2: Building the Bridge - Operational Levers that Unlock Enterprise Value

In Part-1, we made the case that digital sales alone won’t unlock enterprise value unless it’s integrated into a larger commercial vision. Today, we go a step further and explore the operational levers that leadership teams must align to transform isolated digital tools into an enterprise-wide commercial engine.

Because when digital is done right, it doesn’t just make reps more efficient—it makes the business more intelligent.

Unlocking Enterprise Value: From Digital Sales to Commercial Excellence in Pharma

 

Part 1: Rethinking Digital Sales - The First Step Towards Enterprise Transformation

For many pharma companies, digital transformation has become synonymous with smarter sales force tools, video calls, or omnichannel HCP engagement. While these initiatives mark progress, most remain confined to a single function-sales-and often fail to deliver sustainable, enterprise-wide impact.

But what if digital sales could be more than an efficiency play?
What if it could be the gateway to unlocking broader commercial excellence-impacting not just HCP interactions but also brand launch velocity, patient outcomes, and cross-functional collaboration?

When "Digital" Becomes a Dirty Word in Pharma

               “Digital is not the problem. Poor execution is.”

Today, I had a conversation with a senior sales manager from one of the top global pharma MNCs. What he shared was, frankly, alarming.

His team promotes a super-specialized, high-science portfolio that hasn’t changed much in 20+ years. These are legacy brands - well-established, scientifically accepted, and already trusted by specialists.

What “The Omni Advantage” Taught Me About the Future of Pharma Sales

I just finished reading The Omni Advantage: Accelerating the Behavioural Change with Omnichannel in Pharma Sales Engagement by Mehrnaz Campbell (2024), and I can’t stop thinking about it. If you’re in pharma sales, especially in a leadership role, this isn’t just a good read—it’s practically a roadmap.

Let me walk you through what stood out to me, not as a book summary, but as personal takeaways I believe we all need to hear.